Anti-Human CTLA-4 (Ipilimumab) - Fc Muted™ Biotin

Catalogue Number: 12-8058-ABO

Manufacturer:	Abeomics
Type:	Recombinant Monoclonal
Alias:	CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3
Shipping Condition:	Blue Ice
Unit(s):	100 ug
Host name:	Human
Clone:	MDX-010
Isotype:	IgG1, kappa
Immunogen:	Human CTLA-4
Application:	ELISA

Overview
Datasheets

Description

Description: Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body's ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body's own immune response against cancer cells.' Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.

Additional Text

Antibody Clonality

Monoclonal

Application Notes

The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.ELISA

12-8058 Datasheet

Price

£614.00

-

Quantity
Unit Size

Find out about delivery